*Steroids Flashcards

1
Q

Steroid use/misuse

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

STEROID HORMONES

A
  • Cholesterol backbone
  • Sex hormones are a special class of steroids
    that control growth, sexual development and
    behavior
  • Steroids passively cross cell membranes and
    bind to intracellular receptors
  • Glucocorticoids, released during stress,
    suppress the immune respons
    e, increase blood
    glucose, and regulate energy metabolism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Adrenal hormones

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are glucocorticoids responsible for

A

Homeostasis regulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are mineralocorticoids reponsible for

A
  • Fluid and electrolyte balance
  • Wound healing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are androgens responsible for

A

Male sexual characteristics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are progestinsa nd estrogens responsible for

A

Progestins

  • progesterone-like Pregnancy hormone

Estrogens

  • Female sexual charateristics
  • Pregnancy hormone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

GLUCOCORTICOID MECHANISM OF ACTION

A
  • Glucocorticoids are endogenous and synthetic anti-
    inflammatory mediators
  • As lipids, they can passively diffuse across a cell membrane and bind to/active the cytosolic glucocorticoid receptor
  • Once bound, the complex enters the nucleus where it promotes transcription of genes whose products suppress inflammatory pathways
  • Steroids also interfere with the activity of pro-inflammatory transcription factors such as NF-kB and activator protein-1 (AP-1)
  • Steroids are routinely used in overactive immune responses associated with allergy, asthma, AI disease and sepsis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

GLUCOCORTICOID-MEDIATED HOMEOSTASIS

A
  • Physiologic and pharmacologic mechanisms of GC action are
    inherently linked since they are mediated by the same receptor
  • Accordingly, supraphysiologic exposure to corticoids is
    potentially detrimental to several metabolic, hormonal, and
    immunologic functions (importance of taperig)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HYPOTHALAMUS-PITUITARY-ADRENAL AXIS

(Regulation of Corticosteroid Secretion)

A
  • The HPA axis serves the primary role of managing the body’s response to STRESS
  • The end-products of this axis are cortisol, and to some degree, epinephrine, the body’s stress hormones
  • In response to stressful stimuli, cortisol is released for several
    hours
  • Inflammatory and immune diseases are associated with
    cytokine-mediated activation of the HPA-axis, leading to
    cortisol release as an autoregulatory endo product of the
    cascade, thereby linking immune and neuroendocrine pathways
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Glucocorticoid physiology

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ENDOGENOUS ANTIINFLAMMATORY MEDIATION

A
  • Lipocortin (Annexin A-1) is a member of the annexin group of cellular and bloodborne proteins which acts as an endogenous protein inhibitor of the phospholipase A2 (PLA2) enzyme, COX-2 and leukocyte inflammatory
    pathways at multiple levels
  • PLA2 is a primary activation enzyme of the arachidonic acid inflammation pathway
  • During the inflammatory response, annexin A-1 is mobilized to the cell surface where it conversely assumes a dual role: inhibiting the innate immune response and promoting the adaptive T-cell response
  • Induction of expression of the annexin-A1 gene is the main anti-inflammatory, immunosuppressive mechanism of glucocorticoids
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

GLUCOCORTICOID EFFECTS

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MMP Role in Biological Processes

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

STEROID TAPERING

A
  • Adrenal cortical atrophy (adrenal crisis) due to HPA axis suppression can result within weeks of steroid therapy initiation
  • Abrupt discontinuation of oral steroid use can result in a
    dramatic HPA axis upregulation due to the suddenly low
    circulating levels
  • Symptoms of abrupt withdrawal include
    headache, lethargy, fainting, weight loss, hypoglycemia, N&V\
  • Tapering the dose down to physiologic levels (equivalent to 5-7.5 mg prednisone) allows the body to gradually ramp up endogenous production
  • Depending on the dose and duration of therapy, tapering may proceed by 2.5-10 mg every 2-7 days
  • Rebound inflammation requires a return to the last dose used prior to the final reduction (examquestion)
  • Relapse is avoided by continuing therapy slightly beyond
    resolution of inflammation
  • Topical ophthalmic steroids should also be tapered,consider ester-based steroids due to their safety profile
  • Some chronic condtions require lifelong low-dose steroid use - corneal transplant, stromal immune corneal disease, chronic uveitis, recalcitrant dry eye disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

STEROID ADMINISTRATION

A
  • Topical
    • Most common route of administration in eye care
  • Oral
    • Renal function is a key concern
  • Inhalation
  • Local injection
  • Intravenous
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Prednisone indications

A
  • Corticosteroid-responsive conditions
  • Adrenal insufficiency
  • MS; acute exacerbation
  • Asthma; acute
  • Asthma; severe persistent
  • Gout; acute
  • COPD exacerbation
  • Alcoholic hepatitis; acute
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

STEROIDS: GENERAL ADVERSE EFFECTS

A

Dose & Duration Dependent

  • Increased hunger
  • Depression
  • Muscle fatigue
  • Cataracts
  • Elevated IOP
  • Hair pattern changes
  • Easy bruising
  • Acne
  • Osteoporosis
  • Swelling
  • Hirsutism
  • glaucoma
  • cataracts
  • hypokalemia
  • Xanthomas
  • Diabetic complications
  • Peptic ulceration
  • Hypertension
  • Mood changes
  • Delayed wound healing
  • Adrenal insufficiency
  • Growth inhibition in kids
  • Immunosuppression
  • Cushing’s syndrome
  • Hypokalemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Topical opthalmic drug interactions and cautions of prednisone

A

Topical Ophthalmic Drug Interactions
• Naphazoline, tetrahydrozyline, phenylephrine: additive
hypertensive effects

Cautions
• Diabetes
• Active infection
• Hypertension
• Myasthenia gravis
• Optic neuritis
• Ocular HSV

20
Q

Relative glucocorticoid potency vs mineralocorticoid influence

A
21
Q

Which cortisones have the longes half lives?

A

Betamethasone and dexamethasone ( 36-72hours)

22
Q

Fludrocortisone

A

Is a potent mineralocorticoid (fluid/electrolyte balance)

23
Q

Which fatty acid has the highest bioavailablity and the greatest anti-inflam potential?

  1. Alpha linoleic acid
  2. Evening primrose oil
  3. Linoleic acid
  4. Eicosapentaenoic acid
A

EPA

Alpha linoleic- plant based, low bioavailability

Evening primrose oil- omega 6

24
Q

Which of the following is a prodrug?

  1. Bromfenac
  2. Keotrolac
  3. Nepafenac
  4. Flubiprofen
A

Nepafenac

25
Q

Which NSAID structural subclass do the majority of topical opthalmic NSAIDs belong?

  1. Salicylates
  2. Acetic acids
  3. Carboxamides
  4. Propionic acids
A

Acetic acids

26
Q

Oral steroid indications

Inflammatory eye diseases

A
  • Scleritis
  • Temporal arteritis
  • Endophthalmitis
  • Ocular Myasthenia Gravis
  • Graves opthalmopathy
  • Idiopathic cranial hypertension
  • Steven’s Johnsons syndrome
  • Posteior segment disease - vitritis, retinitis, choroiditis, papillitus
27
Q
A
28
Q

Drug interactions with steroids

A
  • Barbiturates
  • Phenylbutazone
  • Phenytoin

Anticoagulants

  • Reduced anticoagulant effects
  • Steroids may promote coagulation by reducing prostacyclin levels
29
Q

Steroid contraindications

A
  • Active Viral infection
  • TB positive
  • Fungal infection
  • Immunosupressed
  • Peptic ulcer history
  • Osteoporosis
  • Psychosis
  • Pregnancy
30
Q

Success of topical steroid treatment depends on

A

Type and location of inflammation

most effective ACUTE > SUBACTE >> CHRONIC least effective

Anterior segment inflammation is much more responsive totopical steroids than posterior

31
Q

Ester-based steroids vs classic ketones

A

Ester based steroids have much less potential to causec cataracts or elevated IOP since ketone based steroids are not broken down by anterior chamber esterses

Ketone based- eg prednisolone

Ester based- loteprendol

32
Q

Which steroid is the only ester based steroid?

A

Loteprednol

33
Q

Which opthalmic drug is the only one preserved with sorbic acid instead of BAK?

A

Durezol (difluprednate)

34
Q

Opthalmic steroids

A

NB most potent on list is Durezol (difluprednate)

35
Q

INVELTYS (loteprednol 1% suspension)

A
  • Treatment for post-op pain and inflammation
  • bd dose
  • prior Inveltys- all post op steroids were only approved for qid dose
  • Formulation uniquely employes AMPPLIFY drug delivery technology wich involes Mucus Penetratin Particles that transport loteprednol throug mucus barrier resulting in a 3x increase in corneal penetration andaccess to aqueous humor
36
Q

Lotemax SM Gel 0.38%

A
  • tid treatment of post-op inflammation
  • Submicron particle size for faster drug dissolution in tears
  • 2x greater penetration to aqeous humor vs Lotemax gel 0.5%
  • Gels have lowest BAK concentration in Lotemax family
37
Q

DEXTENZA 0.4mg Dexamethasone (pellet)

A
  • Post-op pain and inflammation
  • Allergic conjunctivitis
  • Removable if necessary via saline irrigation or manual expression
  • Designes to deliver tapered dose
  • Contains fluorescine for visualization
  • Preservative free
38
Q

Topical steroid indications

A
39
Q

Restasis (CYCLOSPORINE-A PF emulsion)

A
  • 11 amino acid cyclic fungal peptide
  • Historically used as an immunosuppressant for organ transplant rejection prophylaxis,rheumatoid arthritis and recalcitrant psoriasis

Mechanism of Action

  • Inhibits the calcineurin-dependent activation of NFkB in inactive T-cells (NFkB normally stimulates IL-2 production and is upregulated by hyperosmolar tears)
  • Inhibits mast cell degranulation
  • Phagocytic function is unaffected
  • Maximum effects after 110-day T-cell lifespan
  • First immunosuppressant to come on the market for dry eye therapy in 16 yo+
  • Refresh Endura (castor oil) vehicle enhances CsA absorption
  • • FDA approved for keratoconjunctivitis sicca at 1gt bid
  • Off-label use in AKC, VKC, meibomitis, MG, GPC, ocular rosacea
  • Adverse reactions: burning >> redness, tearing, discharge, foreign body sensation, pruritus, blur
  • Contraindicated in patients with active ocular infection or known hypersensitivity
40
Q

XIIDRA® Lifitegrast 5% PF solution

A
  • The only FDA-approved topical immunosuppressant indicated to treat both the signs and symptoms of Dry Eye Disease
  • BID dosing in 17+ yo patients
  • Lymphocyte function-associated antigen-1 (LFA-1) antagonist
  • Inhibits T-cell activation by preventing binding of surface receptor to intercellular adhesion molecule commonly overexpressed on the dry ocular surface
  • Common adverse reactions: irritation, dysgeusia, reduced VA
  • Less common adverse reactions: conjunctival hyperemia, headache,tearing, discharge, pruritus, sinusitis
  • Contraindicated in patients with known hypersensitivity (no reference to contraindication for eye infections exists)
41
Q

Cequa (Cyclosporine 0.09%)

A
  • 0.09% solution
  • Due to CsA’s poor water solubility, NCELLTM technology was applied to improve drug delivery and increase tissue penetration
  • NCELLTM technology uses nanomicelles composed of polymers that encapsulate CsA molecules
42
Q

Eysuvis ((loteprednol suspension 0.25%)

A
  • the first corticosteroid indicated for dry eye disease and the
    first drug approved for short term (up to 2 wks) therapy of DED
  • AMPPLIFYTM drug delivery technology employs the
    use of Mucus Penetration Particles that transport loteprednol etabonate through the mucus barrier esulting in a 3X increase in corneal penetration and access to aqueous humor
  • EYsuVIS® is approved for short term (2 wk) treatment of episodic dry eye flares
43
Q

Truetear

A
  • Bluetooth enabled intranasal neuro-stimulator indicated for dry eye disease bid
  • Stimulates trigeminal nerve for 30-180 sec, enhancing basal lacrimation by 3X
  • Studies show increase in meibum & mucin production
44
Q

tyrvayaTM (Varenicline 0.03mg/50ul)

A
  • Indicated for dry eye disease
  • Varenicline 0.03mg/50ul spray volume bid each nostril
  • Originally developed and marketed in a tablet formulation
    under the tradename Chantix®, for smoking cessation
  • Acts as a highly selective cholinergic agonist
  • Stimulates cholinergic receptors of the trigeminal nerve
    leading to an increase in basal tear film production by
    stimulating the lacrimal glands, meibomian glands and
    goblet cells
  • Clinically significant improvement noted in 4 weeks
  • Adverse effects include sneezing >> cough, throat irritation
45
Q

Oxervate®

A
  • Topical Cenegermin-bkbj 0.002% PF ophthalmic solution for use 1 drop 6x/d x 8 wks
  • Supplied in weekly cartons containing 7 multi-dose vials
    requiring refrigeration
  • First-in-class recombinant human nerve growth factor
    (rhNGF)
  • FDA approved 8/2018 with orphan drug classification for 2yo and over for neurotrophic keratitis
  • Adverse effects: eye pain following instillation, corneal
    deposits, foreign body sensation, ocular hyperemia, ocular
    inflammation and tearing
  • Contraindications: ocular infection
46
Q

TEPEZZA

A
  • First and only FDA-approved treatment for TED
  • Teprotumumab-trbw administerd via IV infusion q3wks x 8
    (t1/2=20d)
  • Antagonizes insulin-like growth factor-1 receptor (IGF-1R),
    preventing orbital fibroblast stimulation
  • Adverse reactions include muscle spasm, nausea, alopecia,
    diarrhea, fatigue, hyperglycemia, hearing impairment,
    dysgeusia, headache, and dry skin
47
Q
A